Mycetoma: A Simple Thorn Prick

Every Monday morning at a clinic on the dusty outskirts of the Sudanese capital Khartoum, sufferers of one of the world’s most neglected disease flock to the only place in the world that can offer them specialized care and treatment. Patients stream through the gates limping, on crutches, pushed by worried relatives on rusty wheelchairs or carried. Most have bandaged legs, many are amputees.

Malaria: New research promises to ease access to ASAQ and ASMQ treatment

Access to effective treatment is central in the fight against malaria. The recently published PREGACT study has shown that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of other treatment types. Another success for malaria treatment comes with the World Health Organization’s announcement that the fixed-dose combination of artesunate+mefloquine (ASMQ) shelf-life has been extended from two to three years, which will greatly help with storage and distribution.

What role for DNDi in hepatitis C?

Bernard Pécoul, Executive Director, DNDi
[April 2016]

The barriers to accessing new hepatitis C treatments are a clear illustration of how today’s system of medical innovation is failing to deliver affordable treatments for people in need. So what should the public health community do to address this complete disconnect between highly successful innovation on the one hand, and unacceptably limited access on the other?

 

Call for papers for PLOS WorldLeish-6 Collection

Dr Jorge Alvar, Head of Leishmaniasis, DNDi, and Dr Javier Moreno, Director of WHO Collaborating Center for Leishmaniasis, announce a call for papers on Leishmaniasis for the PLOS WorldLeish-6 Collection. See the PLOS article, calling for papers for the PLOS WorldLeish 6 Collection, as it appeared on the PLOS Blog.

Hepatitis C: Current barriers to treat patients and DNDi’s R&D strategy to address urgent needs

Hepatitis C Infographic - DNDi Project

DNDi, Pharco, and the Ministry of Health Malaysia announced today at the International Liver Congress in Barcelona, Spain, that they signed agreements to test an affordable hepatitis C regimen in Malaysia and Thailand. The treatment, a potentially pan-genotypic combination of ravidasvir and sofosbuvir, will be tested in Malaysia and Thailand with a target price of under $300. DNDi also released its hepatitis C R&D Strategy as well as infographics to explain why there are so many neglected hepatitis C patients.

Chagas disease: Bridging the gap between patients and treatment

cbatista_1Carolina Batista, Regional Medical Director, DNDi Latin America
[February 2016]

Just before the end of 2015, the notorious announcement of the acquisition of benznidazole rights in the USA with the intention to apply for the FDA’s Priority Review Voucher (PRV) has generated innumerous debates and certainly has driven worldwide attention to Chagas. This state of affairs, despite all the buzz around KaloBios’s former CEO, has exposed the dramatic treatment access situation regarding the leading parasitic killer of the Americas. Currently, 99% of the estimated patients endure the lack of diagnostic and medical attention according to PAHO recommendations.
[Español] [Português]

Duámaco Escribano

Chagas Disease
Colombia

Duámaco Escribano is infected with Chagas disease, a parasite borne disease. In the indigenous community to which he belongs, the Koguis – one of the four ethnic groups living in the Sierra Nevada, on the north coast of Colombia – life is not measured in years: it starts with birth and ends with death, however long it may be…

Elsemani Widaa

Dr_Elsemani_Widaa_1Mycetoma
Sudan

Dr Elsemani Widaa is a surgeon from the Mycetoma Research Centre, Sudan,
which is the country’s treatment reference centre for patients’ suffering from the
disease. He has worked at the Centre for over two years, and even in this short
period of time, he has seen and treated hundreds of patients. The challenges
that doctors face in treating mycetoma are many, the most serious of which problem
is the fact that the only available drug for treating the fungal form of the disease
(eumycetoma) is toxic and ultimately ineffective, but currently, it is all there is.

Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities

Graeme BilbeGraeme Bilbe, Research & Development Director, DNDi
[November 2015]

Addressing the lack of patient-adapted treatments for those suffering from neglected diseases is no easy task. DNDi’s initial short-term strategies were designed to quickly provide improved treatments through new formulations or combinations of existing drugs, and/or improved treatment regimens. Six new treatments have been delivered since 2003.

R&D status November 2015: DNDi Filarial diseases programme

[November 2015]

Filarial diseases are caused by parasitic worms of the helminth family. They include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis (also known as African eye-worm). The worms are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.

R&D status November 2015: DNDi Sleeping Sickness programme

[November 2015]
Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the bite of a tsetse fly. While currently its prevalence is declining, 21 million people are still at risk across 36 Sub-Saharan Africa countries with most of the cases occurring in the Democratic Republic of Congo (89% of all cases in 2013).

R&D status November 2015: DNDi Leishmaniasis programme

[November 2015]
The parasite that causes leishmaniasis is transmitted by the bite of a sandfly. Leishmaniasis is a complex group of diseases with over a million new cases occurring every year and 350 million people living at risk worldwide in 98 countries. The most common forms of the disease are visceral leishmaniasis (VL), which is fatal without treatment, and cutaneous leishmaniasis (CL).